Search results for "GFR"
showing 10 items of 206 documents
Mecanismos epigenéticos de resistencia a las terapias anti-EGFR asociada al fenotipo mesenquimal en el cáncer pulmonar
2020
El cáncer de pulmón es la principal causa de muerte por cáncer en los países occidentales. Es resistente a la terapia convencional, metastásico y con una tasa de supervivencia a 5 años del 15%. Las mejoras del diagnóstico genético, junto con los últimos avances en el diseño de inhibidores (generalmente de proteínas quinasas), han proporcionado un beneficio clínico significativo para un subconjunto de pacientes de adenocarcinoma pulmonar (AC) cuyos tumores tienen mutaciones activadoras en genes que codifican proteínas críticas para la progresión tumoral como EGFR. Los inhibidores dirigidos contra el dominio tirosina quinasa (ITQs) de EGFR de 1ª generación erlotinib y gefitinib han demostrado…
MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation
2019
Mesenchymal stromal cells (hMSCs) display a pleiotropic function in bone regeneration. The signaling involved in osteoblast commitment is still not completely understood, and that determines the failure of current therapies being used. In our recent studies, we identified two miRNAs as regulators of hMSCs osteoblast differentiation driving hypoxia signaling and cytoskeletal reorganization. Other signalings involved in this process are epithelial to mesenchymal transition (EMT) and epidermal growth factor receptor (EGFR) signalings through the regulation of Yes-associated protein (YAP)/PDZ-binding motif (TAZ) expression. In the current study, we investigated the role of miR-33a family as a (…
versamenti pleurici maligni: dalle analisi genetiche al trattamento chirurgico
2014
Introduzione: Il versamento pleurico maligno è una complicanza piuttosto frequente di numerosi tumori sia di origine intratoracica che a partenza da organi extratoracici. Il carcinoma polmonare da solo è la seconda causa più comune di versamento pleurico maligno in pazienti con età superiore a 50 anni. Spesso sono pazienti con patologia in fase avanzata con sopravvivenza media non superiore a 8-10 mesi. Nel ricercare nuove strategie terapeutiche, potenziali e interessanti vantaggi sembrano offrirci gli studi in ambito biomolecolare soprattutto per quanto concerne la presenza del gene per l’epidermal growth factor receptor (EGFR) presente a livello del cromosoma 7 in pazienti affetti da tumo…
Anklage, Nachdenken und Idealisierung
2013
Papel de IRS2 en la reparación del daño hepático y cáncer
2019
La resistencia a insulina es una característica típica de la diabetes tipo 2 y la obesidad, patologías vinculadas a un alto riesgo del desarrollo de enfermedades crónicas hepáticas y hepatocarcinoma. Sin embargo, se desconoce el papel que la resistencia a insulina pueda ejercer durante el daño hepático crónico y durante la hepatocarcinogénesis, por lo que se ha abordado esta cuestión a través del estudio del substrato receptor de insulina 2 (IRS2), principal promotor de la señalización de insulina en el hígado. La experimentación llevada a cabo durante este proyecto muestra que la deleción del gen Irs2 en el modelo murino Irs2-/- impide la inducción de Fgf7 en células estromales durante el …
Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl s-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (…
2022
Here, we described the synthesis of novel pyrazole-s-triazine derivatives via an easy one-pot procedure for the reaction of β-dicarbonyl compounds (ethylacetoacetate, 5,5-dimethyl-1,3-cyclohexadione or 1,3-cyclohexadionone) with N,N-dimethylformamide dimethylacetal, followed by addition of 2-hydrazinyl-4,6-disubstituted-s-triazine either in ethanol-acetic acid or neat acetic acid to afford a novel pyrazole and pyrazole-fused cycloalkanone systems. The synthetic protocol proved to be efficient, with a shorter reaction time and high chemical yield with broad substrates. The new pyrazolyl-s-triazine derivatives were tested against the following cell lines: MCF-7 (breast cancer); MDA-MB-231 (tr…
Autoantigens in the trabecular meshwork and glaucoma‐specific alterations in the natural autoantibody repertoire
2019
Abstract Objectives Primary open‐angle glaucoma (POAG) is a neurodegenerative disorder leading to a gradual vision loss caused by progressive damage to the optic nerve. Immunological processes are proposed to be involved in POAG pathogenesis. Altered serological autoantibody levels have been frequently reported, but complete analyses of the natural autoantibodies with respect to disease‐related alterations are scarce. Here, we provide an explorative analysis of pathways and biological processes that may involve naturally immunogenic proteins and highlight POAG‐specific alterations. Methods Mass spectrometry‐based antibody‐mediated identification of autoantigens (MS‐AMIDA) was carried out in…
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors
2011
Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
2015
Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…
2022
Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…